Study guide

11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT

Board Certified Specialist in Renal Nutrition CSR

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Kidney Disease Foundations

1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk

2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment

2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry

3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools

3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss

4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History

4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment

5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality

5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment

6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning

6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances

7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients

7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy

8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy

8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)

9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients

9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD

10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support

10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support

11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities

11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure

12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends

12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories

13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics

13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence

14 Chapter 14: Domain 2 — Care Coordination, Communication & Education

14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support

15 Chapter 15: Domain 3 — Regulations & Quality Management

15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool

16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols

16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways

11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT

Key Takeaways Explain This Topic AI

KDIGO 2022 recommends an individualized HbA1c target ranging from below 6.5% to below 8.0% for people with diabetes and CKD not on dialysis.

HbA1c is less reliable in advanced CKD and dialysis because shortened red-cell survival, ESA therapy, iron and transfusions distort it; glucose monitoring fills the gap.

KDIGO recommends an SGLT2 inhibitor for type 2 diabetes with CKD when eGFR is at least 20, and metformin labeling contraindicates use below eGFR 30.

KDOQI 2020 suggests 0.6–0.8 g protein/kg/day for CKD 3–5 with diabetes and 1.0–1.2 g/kg/day on dialysis; KDIGO 2022 advises 0.8 g/kg/day for non-dialysis CKD.

For hypoglycemia in CKD, use 15 g of fast carbohydrate that is low in potassium (glucose tablets, apple or cranberry juice) instead of orange juice, and recheck in 15 minutes.

Last updated: September 2026

Why diabetes gets its own section

Diabetes is the leading cause of kidney failure in the United States, and the CSR outline names it first among comorbidities. Domain 2 asks you to recommend plans for management of diabetes alongside mineral and bone disorder, cardiovascular disease and protein-energy wasting. Section 7.3 covered how to prioritize diagnoses and recognize "burnout" diabetes. This section covers the interventions.

Glycemic targets and their limits

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD recommends an individualized HbA1c target ranging from <6.5% to <8.0% in people with diabetes and CKD not treated with dialysis. The lower end suits people with few comorbidities, a long life expectancy, hypoglycemia awareness and low hypoglycemia risk. The upper end suits advanced CKD, multiple comorbidities, limited life expectancy or a history of hypoglycemia.

HbA1c becomes less reliable as CKD advances and on dialysis:

  • shortened red-cell survival and blood loss lower HbA1c;
  • ESA therapy and IV iron create a younger red-cell population, which lowers HbA1c;
  • transfusions dilute glycated hemoglobin;

carbamylation from urea can interfere with some assays.

So HbA1c may look "good" while glucose swings widely. Use self-monitored blood glucose or continuous glucose monitoring (CGM) together with HbA1c. On PD, remember that icodextrin makes GDH-PQQ meters read falsely high; use glucose-specific meters.

Kidney function and glucose-lowering drugs

The dietitian does not prescribe, but must recognize drug effects, hypoglycemia risk and kidney-based limits:

Drug class Kidney-related points Nutrition relevance

Metformin FDA labeling contraindicates use below eGFR 30 and advises against starting it at 30–45; KDIGO reduces the dose as eGFR falls Vitamin B12 deficiency with long-term use; GI upset

SGLT2 inhibitors KDIGO recommends them for type 2 diabetes with CKD when eGFR is ≥20 (grade 1A), continued until dialysis or transplant; the benefit is kidney and heart protection Glucose-lowering weakens as eGFR falls; volume depletion; euglycemic ketoacidosis risk with prolonged fasting, very-low-carbohydrate diets or acute illness

GLP-1 receptor agonists KDIGO recommends a long-acting GLP-1 RA when targets are not met on metformin and an SGLT2 inhibitor, or when those cannot be used; the 2024 FLOW trial showed kidney benefit with semaglutide Reduced appetite, nausea and weight loss: guard against protein-energy wasting in dialysis patients

Insulin Kidney clearance falls, so insulin action lasts longer Needs often drop as CKD advances; hypoglycemia risk on dialysis days and with poor intake

Sulfonylureas Glyburide is avoided in CKD because active metabolites accumulate; glipizide is preferred if one is used Prolonged hypoglycemia with skipped meals

DPP-4 inhibitors Most need dose reduction; linagliptin does not Low hypoglycemia risk

Nonsteroidal MRA (finerenone) Recommended by KDIGO for type 2 diabetes with albuminuria despite RAAS blockade; raises potassium Potassium monitoring and counseling

Protein recommendations with diabetes

KDOQI 2020 (3.0.2, OPINION): for CKD 3–5 with diabetes, 0.6–0.8 g/kg/day under close supervision, to keep nutrition status stable and optimize glycemic control.

KDOQI 2020 (3.0.4, OPINION): on maintenance HD or PD with diabetes, 1.0–1.2 g/kg/day, and more if needed to manage glycemic swings.

KDIGO 2022: about 0.8 g/kg/day for people with diabetes and CKD not on dialysis, and 1.0–1.2 g/kg/day on dialysis.

Know both sources. A question citing KDOQI expects 0.6–0.8 g/kg for non-dialysis CKD with diabetes, while one citing KDIGO expects 0.8 g/kg.

Carbohydrate planning

Consistent carbohydrate at meals, matched to the insulin or medication plan.

Quality: favor fiber-rich, minimally processed carbohydrate; choose lower-potassium whole grains and legumes in portions that fit the potassium and phosphorus plan.

Hidden carbohydrate in renal "safe" foods: hard candy, gumdrops, marshmallows and lemonade are often used to add calories on renal diets but can wreck glucose control. Offer lower-glycemic calorie sources such as unsaturated fats.

Beverages: sugar-sweetened drinks add both glucose and fluid.

Dialysis-specific glycemic issues

Hemodialysis: most dialysate contains about 100 mg/dL of glucose. Insulin clearance changes on dialysis days, and patients often skip meals around treatment, so hypoglycemia is common during and after HD. Plan a snack or meal around the session and review insulin timing with the prescriber.

Peritoneal dialysis: dextrose absorption adds carbohydrate every day. Count it in the meal plan; icodextrin for the long dwell reduces glucose exposure.

Burnout diabetes: falling insulin requirements and normal-looking HbA1c in advanced CKD call for de-escalating therapy (see section 7.3).

Treating hypoglycemia with kidney disease in mind

Use the 15-15 approach : take 15 g of fast-acting carbohydrate, recheck glucose after 15 minutes, and repeat if still low. Choose sources low in potassium and phosphorus:

  • Good choices (about 15 g carbohydrate) Avoid as the usual treatment
  • 3–4 glucose tablets, or 1 tube of glucose gel Orange juice (high potassium)
  • 4 oz apple, cranberry or grape juice Milk or chocolate (phosphorus; fat slows absorption)
  • 1 tablespoon of sugar or honey Large volumes of any drink in fluid-restricted patients

Glucose tablets add the least fluid, potassium and phosphorus. Once glucose recovers, a small snack with protein helps prevent a recurrence if the next meal is more than an hour away.

Monitoring and documentation

Useful diagnoses include Inconsistent carbohydrate intake (NI-5.8.4) and Excessive carbohydrate intake (NI-5.8.2) . For glucose patterns driven by medication or dialysis, Altered nutrition-related laboratory values (NC-2.2) is appropriate. Track glucose logs or CGM reports, hypoglycemia episodes, weight, protein intake and potassium. Coordinate with the nephrologist or endocrinologist whenever a medication change is needed.